Each female BALB/c Nude mouse was inoculated subcutaneously in the right upper flank region with 0.5x10 ⁶of SK-MES-1 tumor cells (a non-small cell lung cancer (NSCLC)cell line having an IL13Ra2 copy number of about 4x104)in 0.1 mL of PBS for tumor development.When the mean tumor size reached about 80-150 mm ³,mice were randomized into respective treatment groups (8 mice per group)and received intravenous injections of PBS vehicle or a single dose of the tested ADC 33-8 at 1 mg/kg on Day 1. The end of the study was day 44.

Each female BALB/c Nude mouse was inoculated subcutaneously in the right upper flank region with 0.5x10 ⁶of SK-MES-1 tumor cells (a non-small cell lung cancer (NSCLC)cell line having an IL13Ra2 copy number of about 4x104)in 0.1 mL of PBS for tumor development.When the mean tumor size reached about 80-150 mm ³,mice were randomized into respective treatment groups (8 mice per group)and received intravenous injections of PBS vehicle or a single dose of the tested ADC 33-8 at 3 mg/kg on Day 1. The end of the study was day 44.

Each female BALB/c Nude mouse was inoculated subcutaneously in the right upper flank region with 0.5x10 ⁶of SK-MES-1 tumor cells (a non-small cell lung cancer (NSCLC)cell line having an IL13Ra2 copy number of about 4x104)in 0.1 mL of PBS for tumor development.When the mean tumor size reached about 80-150 mm ³,mice were randomized into respective treatment groups (8 mice per group)and received intravenous injections of PBS vehicle or a single dose of the tested ADC 33-8 at 6 mg/kg on Day 1. The end of the study was day 44.

Each female BALB/c Nude mouse was inoculated subcutaneously in the right upper flank region with 0.5x10 ⁶of SK-MES-1 tumor cells (a non-small cell lung cancer (NSCLC)cell line having an IL13Ra2 copy number of about 4x104)in 0.1 mL of PBS for tumor development.When the mean tumor size reached about 80-150 mm ³,mice were randomized into respective treatment groups (8 mice per group)and received intravenous injections of PBS vehicle or a single dose of the tested ADC 33-8 at 10 mg/kg on Day 1. The end of the study was day 44.

Each female BALB/c Nude mouse was inoculated subcutaneously in the right upper/lower flank region with 1x10 ⁷of H2228 tumor cells (an NSCLC cell line having an IL13Ra2 copy number of about 2,000)in 0.1 mL of PBS mixed with MATRIGELR (1:1)for tumor development.When the mean tumor size reached about 80-150 mm ³,mice were randomized into respective treatment groups (10 mice per group)and received intravenous injections of vehicle or a single dose of the tested ADCs at 10 mg/kg on Day 1. Body weights and tumor volumes were measured twice per week until the end of the study (Day 48).

Each female BALB/c Nude mouse was inoculated subcutaneously in the right upper flank region with 0.5x10 ⁶of SK-MES-1 tumor cells (a non-small cell lung cancer (NSCLC)cell line having an IL13Ra2 copy number of about 4x104)in 0.1 mL of PBS for tumor development.When the mean tumor size reached about 80-150 mm ³,mice were randomized into respective treatment groups (10 mice per group)and received intravenous injections of PBS vehicle or a single dose of the tested ADCs at 10 mg/kg on Day 1. The end of the study was day 49.

Each female NOD.Cg-Prkdcscid II2rgmIVst/Vst (NPG)mouse was inoculated subcutaneously in the right upper flank region with 1x10 ⁷of H1792 tumor cells (an NSCLC cell line having an IL13Ra2 copy number of about 47000)in 0.1 mL of PBS mixed with MATRIGELR (1:1)for tumor development.When the mean tumor size reached about 80-150 mm ³,mice were randomized into respective treatment groups (10 mice per group)and received intravenous injections of vehicle or a single dose of the tested ADCs at 10 mg/kg on Day 1. Body weights and tumor volumes were measured twice per week until the end of the study (Day 57).

0.5x10⁶of A375 tumor cells (a melanoma cancer cell line having an IL13Ra2 copy number of 3.5x10⁵measured as described in Example 11)mixed in 1:10 dilution of MATRIGELR (Corning Life Sciences)with serum free media was implanted subcutaneously at the hind right flank in female BALB/c Nude mice on Day-10.When the average tumor volume reached about 140 mm³,mice were randomized into respective treatment groups (10 mice per group)and received intravenous injections of PBS vehicle or the tested ADC 33-8 just on Day 1 with a dose of 3 mg/kg. Body weights and tumor volumes were measured twice per week until the end of the study. Days post-dosing 18, the TGI (vs isotype ADC) was calculated.

Female athymic nude-Foxnlnu mice were implanted (left flank)with patient tumor cells. H score: 225. Tumor cells from one NSCLC patient were tested. When sufficient stock animals reached 1000-1500 mm ³,tumors were harvested for re-implantation into pre-study animals.Pre-study animals were implanted unilaterally on the left flank with tumor fragments harvested from stock animals.When the average tumor volume reached 150-300 mm ³on Day 0,mice were randomized into respective treatment groups and received intravenous injections of vehicle or the tested ADC 33-8 (5mg/kg).Body weights and tumor volumes were measured twice per week until the end of the study.Any animal exhibiting>20%net weight loss for a period lasting 7 days or mice displaying>30% net weight loss when compared to Day O was considered moribund and euthanized. Beginning on Day 0,tumor dimensions were measured twice weekly by digital caliper,and data including individual and mean estimated tumor volumes (Mean TV± SEM)was recorded for each group;tumor volume was calculated using the formula (1): TV=width2xlengthx0.52.

Each female BALB/c Nude mouse was inoculated subcutaneously in the right upper flank region with 0.5x10 ⁶of SK-MES-1 tumor cells (a non-small cell lung cancer (NSCLC)cell line having an IL13Ra2 copy number of about 4x104)in 0.1 mL of PBS for tumor development.When the mean tumor size reached about 80-150 mm ³,mice were randomized into respective treatment groups (8 mice per group)and received intravenous injections of PBS vehicle or a single dose of the tested ADC 33-2 at 1 mg/kg on Day 1. The end of the study was day 44.

Each female BALB/c Nude mouse was inoculated subcutaneously in the right upper flank region with 0.5x10 ⁶of SK-MES-1 tumor cells (a non-small cell lung cancer (NSCLC)cell line having an IL13Ra2 copy number of about 4x104)in 0.1 mL of PBS for tumor development.When the mean tumor size reached about 80-150 mm ³,mice were randomized into respective treatment groups (8 mice per group)and received intravenous injections of PBS vehicle or a single dose of the tested ADC 33-2 at 3 mg/kg on Day 1. The end of the study was day 44.

Each female BALB/c Nude mouse was inoculated subcutaneously in the right upper flank region with 0.5x10 ⁶of SK-MES-1 tumor cells (a non-small cell lung cancer (NSCLC)cell line having an IL13Ra2 copy number of about 4x104)in 0.1 mL of PBS for tumor development.When the mean tumor size reached about 80-150 mm ³,mice were randomized into respective treatment groups (8 mice per group)and received intravenous injections of PBS vehicle or a single dose of the tested ADC 33-2 at 6 mg/kg on Day 1. The end of the study was day 44.

Each female BALB/c Nude mouse was inoculated subcutaneously in the right upper/lower flank region with 1x10 ⁷of H2228 tumor cells (an NSCLC cell line having an IL13Ra2 copy number of about 2,000)in 0.1 mL of PBS mixed with MATRIGELR (1:1)for tumor development.When the mean tumor size reached about 80-150 mm ³,mice were randomized into respective treatment groups (10 mice per group)and received intravenous injections of vehicle or a single dose of the tested ADCs at 10 mg/kg on Day 1. Body weights and tumor volumes were measured twice per week until the end of the study (Day 48).

Each female BALB/c Nude mouse was inoculated subcutaneously in the right upper flank region with 0.5x10 ⁶of SK-MES-1 tumor cells (a non-small cell lung cancer (NSCLC)cell line having an IL13Ra2 copy number of about 4x104)in 0.1 mL of PBS for tumor development.When the mean tumor size reached about 80-150 mm ³,mice were randomized into respective treatment groups (8 mice per group)and received intravenous injections of PBS vehicle or a single dose of the tested ADC 33-2 at 10 mg/kg on Day 1. The end of the study was day 44.

Each female BALB/c Nude mouse was inoculated subcutaneously in the right upper flank region with 0.5x10 ⁶of SK-MES-1 tumor cells (a non-small cell lung cancer (NSCLC)cell line having an IL13Ra2 copy number of about 4x104)in 0.1 mL of PBS for tumor development.When the mean tumor size reached about 80-150 mm ³,mice were randomized into respective treatment groups (10 mice per group)and received intravenous injections of PBS vehicle or a single dose of the tested ADCs at 10 mg/kg on Day 1. The end of the study was day 49.

Each female NOD.Cg-Prkdcscid II2rgmIVst/Vst (NPG)mouse was inoculated subcutaneously in the right upper flank region with 1x10 ⁷of H1792 tumor cells (an NSCLC cell line having an IL13Ra2 copy number of about 47000)in 0.1 mL of PBS mixed with MATRIGELR (1:1)for tumor development.When the mean tumor size reached about 80-150 mm ³,mice were randomized into respective treatment groups (10 mice per group)and received intravenous injections of vehicle or a single dose of the tested ADCs at 10 mg/kg on Day 1. Body weights and tumor volumes were measured twice per week until the end of the study (Day 57).